Navigation Links
Trovagene Expands Business Development Efforts Through a Partnership with Leomics Associates, Inc.
Date:2/27/2012

SAN DIEGO, Feb. 27, 2012 /PRNewswire/ -- Trovagene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, today announced that it has hired Leomics Associates, Inc. to expand its business development activities and monetize the company's high value intellectual property estate.

"Trovagene owns a significant portfolio of molecular diagnostic intellectual property with relevance for a broad array of clinical applications. While the company will focus its internal R&D efforts on laboratory-developed tests in oncology, we are seeking development and commercialization partners for in-vitro diagnostic (IVD) opportunities, and for the development of tests in other clinical areas such as infectious disease, non-invasive prenatal diagnostics, transplant medicine, and others," stated Antonius Schuh, Ph.D.,Trovagene's Chief Executive Officer. "We are pleased to be working with Leomics Associates to execute on our business development strategy. The firm's principals have a proven track record in the industry and, amongst others, led the development of the molecular diagnostic testing business of Quest Diagnostics, the largest laboratory testing business in the United States." 

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine.

Trovagene has a dominant patent position as it relates to transrenal molecular testing. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myeloid leukemia (AML) and mutations in the SF3B1 gene, which have been shown to be associated with chemotherapy response in CLL (chronic lymphocytic leukemia) patients.

Trovagene has filed a Form 10 with the SEC. More complete current information about Trovagene is contained in the filing.

About Leomics Associates, Inc.

Leomics Associates, Inc. is a molecular diagnostics-focused consulting firm with ten years of experience, having contributed to some of the most successful molecular diagnostic projects in the industry. Leomics is led by Dr. Jorge Leon, a pioneer in the development and commercialization of molecular diagnostics, who, amongst others, helped establish the molecular diagnostic testing business at Quest Diagnostics and led its development and strategy through their critical growth years.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.

Contacts

Trovagene, Inc.
Stephen Zaniboni
Chief Financial Officer
+1 (858) 496-7466
szaniboni@trovagene.com
http://www.trovagene.com

Venanzio Ciampa
+1 (212) 217 9065
venanzio@thepromofact.com


'/>"/>
SOURCE Trovagene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bayer Expands Its Hemophilia Leadership Development Program
2. AMPAC Fine Chemicals Expands Into Controlled Substance Manufacturing
3. Sanovas Expands Headquarters and Opens Manufacturing Site
4. PAREXEL Expands Alliance Network to Support Early Phase Patient Studies, Establishes Collaboration With University Hospitals Bristol NHS Foundation Trust
5. CutisPharma Expands Product Line with New Oral Suspension Prescription Compounding Kits
6. Myoderm Expands International Capabilities
7. FDA Expands Use of Endovascular Graft to Treat Aortic Tears
8. Particle Sciences Expands Its DOSE™ Program With Additional Proprietary Modeling Capabilities
9. FDA Expands Use of Prevnar 13 Vaccine for People Ages 50 and Older
10. Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires
11. FDA Expands Use of HIV Drug Isentress to Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... , July 10, 2017  The tenth annual ... Boston, MA at the Sheraton Boston Hotel, ... unparalleled access to global decision makers and innovative biotech ... life science leaders during two impactful days. BioPharm America ... delegates with additional networking opportunities with 4,500+ life science ...
(Date:7/5/2017)... England , July 5, 2017 Wolfmet ... perfect answer as physics and manufacturing combine to progress molecular ... thyroid, existing SPECT systems are unable to accurately quantify the ... only limited information regarding the success of this radiotherapy treatment ... ...
(Date:7/5/2017)... 5, 2017   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... ("BioLife"), today announced that it has reached an agreement ... largest shareholder, to modify its existing credit facility effective ... modification, WAVI agreed to exchange its existing $4.25 million ...
Breaking Medicine Technology:
(Date:7/25/2017)... ... July 25, 2017 , ... Creative ... their partnership to provide the Pharmacist eCare Plan to Computer-Rx pharmacies ... country with the ability to develop the Pharmacist eCare Plan, a shared document ...
(Date:7/25/2017)... ... July 25, 2017 , ... Nautilus ... United States, today announced its partnership with financial technology company, Automated Transaction Delivery ... of the solution lies within Hyosung’s superior ATMs, assisted self-service devices and associated ...
(Date:7/25/2017)... , ... July 25, 2017 , ... SignatureCare Emergency Center ... the Austin, TX area 24 Hours a day. , The Emergency Room ... , “We’ve been open four months now and things are running smoothly,” said ...
(Date:7/24/2017)... ... ... SignatureCare Emergency Center is looking to award their 2017 Fall Scholarship. ... student. Get your applications in now as the deadline is approaching fast. ... a nursing student at Prairie View A&M University with a 3.45 GPA. Castillo was ...
(Date:7/24/2017)... ... July 24, 2017 , ... A four alarm ... construction site and threatened numerous homes and businesses nearby, causing some 700 individuals ... NBCLosAngeles.com. Los Angeles Area consulting firm Fire Protection Group, Inc. notes that the ...
Breaking Medicine News(10 mins):